medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 5

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (5)


Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil

Sette-Jr H, Cheinquer H, Wolff FH, de Araujo A, Coelho-Borges S, Soares SRP, Barros MFA

Idioma: Ingles.
Referencias bibliográficas: 34
Paginas: 727-733
Archivo PDF: 178.13 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatology 2014; 61: 45-57.

  2. Li B, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-16.

  3. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, Moore RD, et al. Relationship of liver disease stage and antiviral therapy with liver- related events and death in adults co-infected with HIV/ HCV. JAMA 2012; 308: 370-8.

  4. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  5. Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016; 64: 370-80.

  6. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016; 64: 360-9.

  7. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016; 63: 1493-505.

  8. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373: 714-25.

  9. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35.

  10. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 2016; 63: 1430-41.

  11. Afdhal N, Zeuzem S, Kwo P, Choijkier M, Gitlin N, Puoti M, Romero-Gomez M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.

  12. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.

  13. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649-59.

  14. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-65.

  15. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, et al. PEARL-III Study; PEARL-IV Study. ABT-450/ r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.

  16. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffmann ML, et al. ABT-450/r- ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-82.

  17. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, De Jesus E, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.

  18. Dieterich D, Bacon BR, Flamm SL, Kowdley KV, Milligan S, Tsai N, Younosi Z, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220A.

  19. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virologial response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016 [Epub ahead of print].

  20. Foster GR, Irving WL, Cheung MCM, Walker AJ, Hudson BE, Verma S, McLaugchlan J, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64: 1224-31.

  21. Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, et al, for the HCV-TARGET Study Group. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology 2016; 150: 419-29.

  22. Gallego A, Alvarado E, Gely C, Pagès N, Masip M, Margall N, Torras X, et al. Treatment with sofosbuvir + simeprevir for 12 weeks in HCV compensated cirrhosis (genotypes 1 and 4); the use of ribavirin dos not influence sustained viral response. J Hepatol 2016; 64: S741.

  23. Salomoni E, Gianni E, Gragnani L, Oliveri F, Brunetto MR, Luchi S, Bartolozzy D, et al. High SVR rates with SMV + SOF in HCV GT1 and GT4 patients with cirrhosis or advanced fibrosis: a real practice analysis from a large regional database in Tuscany, Italy. J Hepatol 2016; 64: S761-S762.

  24. Ramos H, Gómes J, Linares P, Martín I, Almohalla C, Jorquera F, García I, et al. Simeprevir and Sofosbuvir with or without ribavirin in genotype 1 chronic hepatitis C patients: efficacy and safety in real life. J Hepatol 2016; 64: S765-S766.

  25. Gaeta GB, Menzaghi B, D'Offizzi G, Giorgini A, Lazzarin A, Babudieri S, Brunetto M, et al. Effectiveness of simeprevir treatment for hepatitis C in real practice: preliminary results from the Stily Italian Observational Study. J Hepatol 2016; 64: S770-S771.

  26. Mariño Z, Pascasio JM, Sánchez-Antolin G, Baliellas C, Prieto M, Moreno JM, Carrion JA, et al. Safety and efficacy of sofosbuvir plus simeprevir in a Spanish Cohort of 622 cirrhotic patients infectec with genotypes 1 or 4. J Hepatol 2016; 64: S831.

  27. Lisboa-Neto G, Noble CF, Pinho JR, Malta FM, Gomes-Gouvêa MS, Alvarado-Mora MV, da Silva MH, et al. Resistance mutations are rare among protease inhibitor treatment-naïve hepatitis C genotype-1 patients with or without HIV coinfection. Antivir Ther 2015; 20: 281-7.

  28. Mendizabal M, Gallardo PE, Haddad L, Adrover R, Ferrada A, Aravena E, Roblero JP, et al. Safety and effectiveness of Paritaprevir/r/Ombitasvir/Dasabuvir ± Ribavirin in Genotype 1 and 4 HCV infected patients treated in real life settings: A South American cohort experience. Ann Hepatol 2016; 15: A992-3.

  29. Soza A, Monrroy H, Labbé P, Urzúa A, Aravena E, Holguín J, Varón A, et al. Effectiveness of asunaprevir plus daclatasvir in patients with hepatitis C virus and advanced fibrosis: real-world experience from the LALREAN Network. Ann Hepatol 2016; 15: A998.

  30. Vargas JI, Monrroy H, Beckmann A, Arrese M, Nenítez C, Barrera F, Soza A. Results of all-oral therapy for chronic hepatitis C in a single center. Ann Hepatol 2016; 15: A1000.

  31. Chirino-Sprung RA, Dehesa M, Wolpert E, Corona-Lau C, Garcia-Juarez I, Moctezuma-Velázquez C, Sánchez-Avila JF, et al. Chronic hepatitis C treatment with direct acting antiviral agents in a real life setting. Ann Hepatol 2016; 15: A999.

  32. Naveira MCM, Almeida EC, Cattapan E, Fernandes N, Gomes JN, Graner B, Santos ME, et al. New antivirals for hepatitis C in Brazil: preliminary effectiveness analysis with current national databases. Ann Hepatol 2016; 15: A999.

  33. Ferrada A, Urzúa A, Pérez-Luco T, Molina n, González K, Aravena E, Arancibia JP, et al. Two interferon-free regimens for genotype 1 hepatitis C. Report of treatment "real life" in patients in Chile. Ann Hepatol 2016; 15: A993.

  34. Malé-Velázquez R, De La Cabada-Bauche J, Mireles-Alvarez CA, Hernández-Jaime M, Medina-Medrano MA, Colunga-Lozano LE, De La Torre Gonález P, et al. Real life experience with interferon-free direct acting antivirals (IFDAA) in Mexican patients with chronic hepatitis C infection. Ann Hepatol 2016; 15: A994.




2020     |     www.medigraphic.com